Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Andre Moreira

Colon & Rectal Surgery New York, NY Medical Doctor

NPI 1194981506 CMS profile 8404803

530 1St Ave Ste 7V, New York, NY 10016

Open in the dashboard

General payments

$9,452

149 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andre Moreira of New York, NY is reported in the CMS Open Payments database as having received $9,452 across 149 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Colon & Rectal Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,725 52
2024 General $546 21
2023 General $638 29
2022 General $6,145 29
2021 General $397 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andre Moreira
  • Colon & Rectal Surgery median
  • Middle half of Colon & Rectal Surgery
  • National median

In program year 2025, general payments to Andre Moreira were reported at $1,725. Among 1,481 Colon & Rectal Surgery profiles paid that year, the median was $317 and the middle half received between $109 and $1,248.

Show as a table
Year Andre Moreira Colon & Rectal Surgery median Middle half National median
2019 $0 $443 $125–$2,179 $163
2020 $0 $167 $53–$931 $114
2021 $397 $207 $72–$1,272 $132
2022 $6,145 $341 $111–$1,587 $149
2023 $638 $322 $115–$1,420 $160
2024 $546 $328 $112–$1,354 $164
2025 $1,725 $317 $109–$1,248 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Intuitive Surgical, Inc. $5,696 12 payments
  2. AbbVie, Inc. $1,427 38 payments
  3. Janssen Biotech, Inc. $867 24 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $696 42 payments
  5. Celgene Corporation $373 16 payments
  6. Nestle HealthCare Nutrition Inc. $106 4 payments
  7. Ferring Pharmaceuticals Inc. $98 3 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $73 4 payments
  9. Lilly USA, LLC $43 2 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $22 1 payment
  11. Other $50 3 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,346 139 payments
  2. Travel and Lodging $3,014 7 payments
  3. Education $2,517 2 payments
  4. Consulting Fee $575 1 payment
Products named General payments · program years 2021–2025
  1. Da Vinci Surgical System $3,196 11 payments
  2. DAVINCI XI $2,500 1 payment
  3. TREMFYA $668 19 payments
  4. ENTYVIO $596 39 payments
  5. RINVOQ $591 27 payments
  6. ZEPOSIA $373 16 payments
  7. SKYRIZI Immunology $302 17 payments
  8. SKYRIZI Immunology $235 8 payments
  9. STELARA $198 5 payments
  10. HUMIRA $159 6 payments
  11. Other $529 22 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$55,215

Medicare's payments for the services billed

Medicare patients

76

Average age 72

Services billed

200

41 women, 35 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 53%
Diabetes 36%
Ischemic heart disease 34%
Chronic kidney disease 34%
Depression 33%
Cancer 29%
COPD 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
STELARA
  • Janssen Biotech, Inc. $198
$198 — —
TREMFYA
  • Janssen Biotech, Inc. $101
$101 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $84
$84 — —
RINVOQ
  • AbbVie, Inc. $62
$62 — —
SKYRIZI
  • AbbVie, Inc. $62
$62 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

149 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Colon & Rectal Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record